To help treat the effects of Covid-19, President Donald Trump has reportedly received dexamethasone. Deck-of-who-the-phone? Dexys Midnight Runners hold the phone? No, dexamethasone. It is a ...

Dexamethasone became the latest drug to get attention for its potential in treating COVID, when a study declared this week there were promising results in trials with the drug. But what exactly is ...

Dexamethasone oral tablet is a generic drug that’s prescribed for many conditions, including allergic reactions and inflammation. Dexamethasone belongs to a class of drugs called corticosteroids (also ...

Treatment with the antiviral remdesivir (Veklury) plus dexamethasone was linked to fewer deaths among patients hospitalized for COVID-19 compared with dexamethasone monotherapy, a retrospective study ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Dexamethasone may help save up to one-third of patients on ventilators. As the world awaits a COVID-19 vaccine, researchers studying possible treatments have found a commonly used steroid called ...

Dexamethasone treatment failed to demonstrate noninferiority to surgery for chronic subdural hematoma and was associated with more complications and a greater risk of later surgery, according to ...

The president’s physician says President Trump was treated with a steroid after a drop in oxygen levels on Saturday. Dr. Sean Conley said at a news conference on Sunday that he was given the steroid ...

Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the virus responsible for the present coronavirus disease 2019 (COVID-19) pandemic, causes a wide spectrum of ...

CARDIFF, UNITED KINGDOM - JUNE 16: A close-up of a box of Dexamethasone tablets in a pharmacy on June 16, 2020 in Cardiff, United Kingdom. Results of a trial announced today have shown that ...

Among patients with glioblastoma (GBM) receiving an immune checkpoint inhibitor, those who received dexamethasone at baseline for cerebral edema had significantly worse overall survival, according to ...

Santen EMEA and NTC are delighted to announce that the results of their phase III clinical study, LEADER7, have been published in Eye. The study demonstrated for the ...